Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. - Wikidata - wikimedia - TriplyDB

Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.

Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.

http://www.wikidata.org/entity/Q36903680

about

Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms.Increasing Resistance to Extended-Spectrum Cephalosporins, Fluoroquinolone, and Carbapenem in Gram-Negative Bacilli and the Emergence of Carbapenem Non-Susceptibility in Klebsiella pneumoniae: Analysis of Korean Antimicrobial Resistance Monitoring S Tuning the properties of the bacterial membrane with aminoacylated phosphatidylglycerol.A novel STK1-targeted small-molecule as an "antibiotic resistance breaker" against multidrug-resistant Staphylococcus aureus.Evaluation of Daptomycin Non-Susceptible Staphylococcus aureus for Stability, Population Profiles, mprF Mutations, and Daptomycin Activity Methicillin-Resistant Staphylococcus aureus: A Growing Risk in the Hospital and in the Community.Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides.Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates.Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure.Current and novel antibiotics against resistant Gram-positive bacteria Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation.Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons Cutaneous infections and infestations: new therapies Frequency and Distribution of Single-Nucleotide Polymorphisms within mprF in Methicillin-Resistant Staphylococcus aureus Clinical Isolates and Their Role in Cross-Resistance to Daptomycin and Host Defense Antimicrobial Peptides Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.Mechanisms of resistance to daptomycin in Enterococcus faecium.The evaluation and treatment of complicated skin and skin structure infections.Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance Pre-clinical experience with daptomycin.High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure.Daptomycin in bone and joint infections: a review of the literature.β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone.Infectious complications in dialysis--epidemiology and outcomes.Roles of tRNA in cell wall biosynthesis.Staphylococcus aureus chronic and relapsing infections: Evidence of a role for persister cells: An investigation of persister cells, their formation and their role in S. aureus disease.Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus.A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections.Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model.Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus.Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.Phenotypic and genotypic correlates of daptomycin-resistant methicillin-susceptible Staphylococcus aureus clinical isolates.

P2860

Q26853465-AC5C8029-B69A-473C-B514-D9BD6F7F4B06 Q29616084-C4902BAE-CDE5-45C5-A553-E7CADBECC602 Q30452801-1778DE86-387C-41F9-9CC8-5B81B440AE62 Q31131146-BB65337F-AA12-48E3-AAE0-BED25C39A440 Q31164789-B50B8E06-2DFC-49E1-BC51-A942F291DADF Q33507347-63A472BC-6820-4FF9-930B-B11F3C81EFE8 Q33894853-1E0FE71E-3784-4BAD-A891-18AAF68B8971 Q33939055-37A17A19-3838-4D52-9929-FB547C124B40 Q33970752-5400D8AC-7D0B-4302-837D-B6205EFF956D Q33997671-1722E25F-F92F-49D9-93F2-7E5A9CB79875 Q34045273-DCCAE401-DFF4-47FF-B7EB-B9003E6FC482 Q34045376-B0694047-3EA6-43D0-89C7-4E82E344C983 Q34157657-D3C2279B-8E74-4280-9A3D-431689383836 Q34529205-34315BB3-7FDE-4AB9-8CCC-35B1F8161ACB Q34573702-EF4A1E86-DC6E-4521-9CF3-413202455976 Q34597770-F2924D05-FFCC-459C-BE6A-6E3704067333 Q34779009-0C254CD3-649A-480C-9C6F-B29D22F529BD Q34932588-8A86DBD7-BC11-450E-A0D2-7DE4CD2F9D6E Q35026521-8D6428F3-9608-4915-B42A-0A16BBA4188B Q35139449-ECCBAF53-2790-4275-B074-6F00B21C3887 Q35256159-0D273290-AD17-4A4C-9A82-72863A4C839A Q35628618-64AA348B-72B8-4AD5-8955-8D06A6995A45 Q35860154-1BDE2E38-9FEC-4FA7-A85C-D6636E1EF997 Q36364106-C25F64A8-D34F-4E82-941B-793FC7467945 Q36482920-399D0B1D-BB9C-42C4-B043-C179E511E381 Q37111836-8B238858-6156-4923-9E8F-6556BE464954 Q37263514-6E3E2516-0950-4505-A606-8BA10983AD53 Q37284356-1CCBD555-C823-4B34-825D-FD97E1731883 Q37291084-4C55BB2A-3AD6-4D47-9D04-3F8257B046FD Q37319460-7FC9AC12-15D1-4CD8-A3B2-827FF19CFDF3 Q37544579-2C5623AB-0988-45B0-B1DD-EB886840E613 Q37969996-7512F4D6-DA93-435E-BE25-7C8B5638CD8C Q37977400-8B89791D-24BF-47C0-A92E-6CE827804096 Q38237595-C8C66A7F-E13C-4CB3-A761-C548548AADC9 Q38369089-B2628141-4E11-4641-8073-9E35D75521EB Q38530316-C54E5957-34E9-4C9A-B4D4-97BF710E3021 Q38626860-82836823-7166-47A3-A205-166D18F2EE40 Q38627239-CBA163BB-FDB2-485E-A05D-896C65241E90 Q38895642-751042D8-11F4-452E-AA36-39F0A8FBE306 Q39000860-33656118-97D4-4D74-B8E1-CFE162945B0D

P2860

Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.

http://www.wikidata.org/entity/Q36903680

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Perspectives on Daptomycin res ...... ance in Staphylococcus aureus.

@en

type

label

Perspectives on Daptomycin res ...... ance in Staphylococcus aureus.

@en

prefLabel

Perspectives on Daptomycin res ...... ance in Staphylococcus aureus.

@en

P1433

Q36903680-E588F48E-271A-4DCA-97CE-ED287B6B0C7E

P1476

Q36903680-762BE2E9-B023-4D78-A7E5-933D6B9191F0

P2093

Q36903680-4D71120E-75F5-4EED-9143-9F9F689C58E8

Q36903680-CAA4D3E0-4EA2-42B9-9157-3DABB59C843A

P2860

Q36903680-00D5FC28-C401-487D-B024-8A5EA171F718

Q36903680-033FFE32-26FC-4CB3-9609-7D3DD9AF9A0F

Q36903680-0F20E54F-40D7-4F27-8767-19859EC1434D

Q36903680-11785F03-12C5-49DB-89DB-603476F004D4

Q36903680-139A07B3-04E9-40A8-BE88-FAC2E3E13086

Q36903680-1441BF62-4DA1-42C0-87C2-52FB49F29223

Q36903680-26A63D02-603A-4840-BACD-3958B42A8C9E

Q36903680-2A807C7B-C41C-4C12-BBDE-12815D3993C0

Q36903680-2E26E08E-3931-4233-B39D-9688779A5195

Q36903680-2F4DC9A4-FE18-4E35-810C-190F43475344

P304

Q36903680-3B5EC561-52E4-430A-87B0-0114A92E47BF

P31

Q36903680-C9ABF4E6-E207-4C8B-9D9F-275DA62A05E8

P356

Q36903680-BC741847-1D0D-4692-B198-9C03B3A7F649

P407

Q36903680-6D0384B8-9020-47B9-8CFB-C654829326BD

P433

Q36903680-6650F481-F37D-4E4F-9672-8689772E4EAA

P478

Q36903680-59933D58-36DD-4F70-A489-EEE859602D63

P577

Q36903680-1AA98EDD-E39F-43F1-84BC-B7066E53CAF2

P5875

Q36903680-F51D7223-68C1-4733-A17B-898C4D042490

P698

Q36903680-2DD39E1E-94E2-4152-B26E-B54ADFCC14C4

P356

P1433

Clinical Infectious Diseases

P1476

Perspectives on Daptomycin res ...... ance in Staphylococcus aureus.

@en

P2093

George Sakoulas

http://www.w3.org/2001/XMLSchema#string

Helen W Boucher

http://www.w3.org/2001/XMLSchema#string

P2860

Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.

Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.

Resistance studies with daptomycin

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

P304

601-608

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/520655

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6156540

http://www.w3.org/2001/XMLSchema#string

P698

17682996

http://www.w3.org/2001/XMLSchema#string